BACE Hopes Finally Fizzle As Biogen/Eisai End Elenbecestat Alzheimer's Studies

 
• By Mandy Jackson
  
alzheimer's disease on MRI - Image
Elenbecestat was the last BACE inhibitor left in clinical trials. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D